High expression of DYNC1I1 was associated with poor prognosis and promoted the proliferation and migration of gastric cancer cells by upregulating IL-6 expression, which suggests that DYNC1I1 may be a potential therapeutic target for gastric cancer [67,68]. Here, IL6 is linked to gastric cancer.